Cargando…
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial
BACKGROUND: Additional outpatient therapies which are readily accessible will be essential to reduce COVID-19 illness progression in high risk individuals. Especially as the virus continues to mutate with greater transmissibility despite increased global vaccination. METHODS: A randomized, double-bl...
Autores principales: | Tandon, Monika, Wu, Wen, Moore, Keith, Winchester, Stephen, Tu, Yuan-Po, Miller, Christopher, Kodgule, Rahul, Pendse, Amol, Rangwala, Shabbir, Joshi, Shashank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239922/ https://www.ncbi.nlm.nih.gov/pubmed/35784831 http://dx.doi.org/10.1016/j.lansea.2022.100036 |
Ejemplares similares
-
Correction to “SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial”
por: Tandon, Monika, et al.
Publicado: (2022) -
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
por: Salvi, Sundeep, et al.
Publicado: (2021) -
Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection
por: Winchester, Stephen, et al.
Publicado: (2021) -
Prediction of nasal spray drug absorption influenced by mucociliary clearance
por: Shang, Yidan, et al.
Publicado: (2021) -
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021)